Ultragenyx Pharmaceutical (RARE) EBIAT (2016 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed EBIAT for 10 consecutive years, with -$128.6 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 3.49% to -$128.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$575.0 million, a 1.05% decrease, with the full-year FY2025 number at -$575.0 million, down 1.05% from a year prior.
- EBIAT was -$128.6 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$180.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$73.0 million in Q3 2021 to a low of -$245.1 million in Q3 2022.
- A 5-year average of -$145.6 million and a median of -$143.6 million in 2021 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 583.62% in 2021, then skyrocketed 34.87% in 2023.
- Ultragenyx Pharmaceutical's EBIAT stood at -$122.5 million in 2021, then dropped by 23.99% to -$151.8 million in 2022, then increased by 18.63% to -$123.6 million in 2023, then fell by 7.81% to -$133.2 million in 2024, then increased by 3.49% to -$128.6 million in 2025.
- Per Business Quant, the three most recent readings for RARE's EBIAT are -$128.6 million (Q4 2025), -$180.4 million (Q3 2025), and -$115.0 million (Q2 2025).